1. Streptomyces serine protease (DHP-A) as a new biocatalyst capable of forming chiral intermediates of 1,4-dihydropyridine calcium antagonists.
- Author
-
Arisawa A, Matsufuji M, Nakashima T, Dobashi K, Isshiki K, Yoshioka T, Yamada S, Momose H, and Taguchi S
- Subjects
- Amino Acid Sequence, Catalysis, Cloning, Molecular, Gene Expression, Hydrolysis, Molecular Conformation, Molecular Sequence Data, Sequence Homology, Amino Acid, Serine Endopeptidases genetics, Streptomyces genetics, Substrate Specificity, Dihydropyridines metabolism, Serine Endopeptidases metabolism, Streptomyces enzymology
- Abstract
Streptomyces viridosporus A-914 was screened as a producer of an enzyme to effectively form chiral intermediates of 1,4-dihydropyridine calcium antagonists. The supernatant liquid of the growing culture of this strain exhibited high activity for enantioselective hydrolysis of prochiral 1,4-dihydropyridine diesters to the corresponding (4R) half esters. The responsible enzyme (termed DHP-A) was purified to apparent homogeneity and characterized. Cloning and sequence analysis of the gene for DHP-A (dhpA) revealed that the enzyme was a serine protease that is highly similar in both structural and enzymatic feature to SAM-P45, which is known as a target enzyme of Streptomyces subtilisin inhibitor (SSI), from Streptomyces albogriseolus. In a batch reaction test, DHP-A produced a higher yield of a chiral intermediate of 1,4-dihydropyridine than the commercially available protease P6. Homologous or heterologous expression of dhpA resulted in overproduction of the enzyme in culture supernatants, with 2.4- to 4.2-fold higher specific activities than in the parent S. viridosporus A-914. This indicates that DHP-A is suitable for use in reactions forming chiral intermediates of calcium antagonists and suggests the feasibility of developing DHP-A as a new commercial enzyme for use in the chiral drug industry.
- Published
- 2002
- Full Text
- View/download PDF